US Patent

US11123319 — Methods and compositions for treating edema refractory to oral diuretics

Formulation · Assigned to RESQ Pharmaceuticals LLC · Expires 2040-12-04 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for administering bumetanide through intranasal, sublingual, and subcutaneous routes to treat edema resistant to oral diuretics.

USPTO Abstract

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

Drugs covered by this patent

Bumex (BUMETANIDE)

Patent Metadata

Patent number: US11123319
Jurisdiction: US
Classification: Formulation
Expires: 2040-12-04
Drug substance claim: No
Drug product claim: Yes
Assignee: RESQ Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.